What's Being Discussed

Member appeals: The board will privately review individual requests to change health plans or remove dependents from coverage.
Disease management: An update on HMSA's AccordantCare Rare program, which supports members with rare or complex conditions.
Prescription drug costs for retirees: New rates for the prescription drug plan through Caremark and SilverScript, taking effect January 1, 2027.
Staff compensation study: Hiring a consultant to review salaries for certain key exempt employees.
Investment portfolio review: Updates on how the fund's money is invested, including private credit, private equity, and real assets — plus a review of the Investment Policy Statement and a board education session on delegated authority.
Operational reports: Staff will report on member services, enrollment audits, technology projects, wellness programs, and the fund's financial statements as of June 30, 2026.
Carrier reports: Updates from health insurance providers including HMSA, Kaiser Permanente, Humana, CVS Caremark, SilverScript, Hawaii Dental Service, Securian, Verdegard Hawaii, and Vision Service Plan (VSP).

Decisions Expected

Possible approval of updated retiree prescription drug plan rates starting in 2027.
Possible approval to hire a salary consultant for exempt employees.
Possible revisions to the Investment Policy Statement.
Closed-session decisions regarding private investment managers and personnel matters.

Who Should Pay Attention

State and county retirees — especially those affected by upcoming prescription drug rate changes in 2027.
Active state and county employees enrolled in EUTF health benefits.
Dependents currently covered under an EUTF member's plan.
Anyone interested in how Hawaii's public employee health benefits fund manages its money and operations.